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Table S1. Governmental Partners. 
 Army Corps of Engineers 
 California Environmental Protection Agency, Office of Environmental Health Hazard 
Assessment  
 European Chemicals Agency 
 European Joint Research Centre 
 Health Canada 
 L'Institut National de l'Environnement Industriel et des Risques 
 U.S. Food and Drug Administration (National Center for Toxicological Research) 
 U.S. Centers for Disease Control and Prevention, National Center for Environmental Health, 
and Agency for Toxic Substances and Disease Registry 
 U.S. Department of Defense 
 U.S. National Center for Advancing Translational Science 
 U.S. National Institute of Environmental Health Sciences and National Toxicology Program 
 U.S. National Institute for Occupational Safety and Health 
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Table S2: An Illustrative Framework for Evidence Integration Focusing on New Data Types Used in the Prototypes.  
This causal determination framework illustrates how evidence integration and inferences about causality might be conducted using new data types. The left 
column summarizes the prototypes, the middle column presents evidence for causality exemplified by the prototypes, and the right column illustrates how such 
evidence might be integrated and weighed. To simplify the table, the prototypes with shared attributes are aggregated within a Tier. In general, data of equal 
quality data are weighed as follows: human data is preferred over non-human data, target tissue or cell data is preferred over non-target tissue or cell data, 
experimental systems with intact metabolism are preferred over systems without intact metabolism, in situ, tissue and primary cell culture are preferred over cell 
lines. It should be noted that all high quality data types have proved useful in evaluating risks. The Tier 3 of prototypes are unique in that they focus on known 
human health effects and well-documented public health risks in order to verify and anchor NexGen approaches. For the Tier 3 prototypes, the “Evidence 
Integration” column evaluates how successful new data types were in predicting known outcomes. While an example is provided here, our experience with 
evidence integration of various data types is limited and requires additional application experience.  
Modifications of the Bradford-Hill criteria (e.g., consistency, coherence, biological plausibility) continued to be useful in the evaluation of new data types. As 
presented here, confidence in causality ranges from suggestive to likely, largely based on understanding the biological context in which new data types are 
embedded. “Likely” generally applies to the few cases for which the new data types are clearly tied to adverse outcomes through a combination of observational 
and experimental data, and include systems biology understanding. Biological context need not be chemical specific but also can be derived from 
disease/disorder-specific knowledge or from analogy with related chemicals. In practice, many new data types are anticipated to be “suggestive” for the near term 
and most appropriate for screening and prioritization and, perhaps, limited-scope assessments. Of note is that, contrary to traditional approaches, some new 
approaches can be used to estimate relative potencies to perturb important biologic processes as a potential surrogate for clearly identified hazards. We anticipate 
major assessments to be augmented by new data types but, for the near term, they will continue to be based on traditional data. 
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Molecular epidemiology and 
clinical studies: 
 Illustrated that new data types 
(when properly collected, 
analyzed, and reported) 
appear to provide results that 
are comparable to robust, 
traditional human data. These 
new data types could be used, 
when linked by mechanistic 
understanding, to: 
(1) evaluate potential hazards 
posed by chemicals with no or 
limited traditional data, (2) 
augment traditional 
assessments, or (3) better 
 Specific pattern alterations in molecular events appear 
consistently and strongly associated with known intermediate 
events and known hazards at environmental exposure levels (EPA 
2013a, 2015; McCullough et al. 2014; McHale et al. 2009; McHale et 
al. 2012; Smith et al. 2011; Thomas et al. 2014). Data for tobacco 
smoke were reported in the Gene Expression Omnibus or 
ArrayExpress. Also see Cooper et al. 2013 and Hatzimichael and 
Crook 2013, Mattes et al, 2014). 
 Exposure-dose was measured for benzene and ozone using urinary 
biomarkers and radiolabeled ozone, respectively (Hatch et al. 2014; 
McHale et al. 2009; Thomas et al. 2014). Tobacco-smoke exposures 
were self reported, substantially increasing uncertainty for exposure-
dose-response characterization and highlighting the need for accurate 
exposure characterization (EPA 2014). 
 Dose-dependent alterations are observed in concomitantly collected 
data for molecular events and adverse effects, in the range of 
Suggestive to likely: Evidence is consistent, 
coherent, and biologically plausible that the 
observed molecular events are causally related 
to adverse effects. Implications are based on 
comparisons to robust traditional risk 
assessments:  
 For benzene and ozone, identified molecular 
events are likely causally related to known 
adverse outcomes in a dose-dependent 
manner. Mechanistic links between molecular 
events, intermediate effects, and adverse 
outcomes are well understood. Pharmacologic 
intervention that blocks implicated pathways 
also blocks or ameliorates adverse effects. 
Similarly, measured polymorphism within 
identified pathways confers altered risks. 
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inform traditional risk 
assessment issues, such as 
human variability and 
susceptibility, cross- species 
and in vivo-to-in vitro 
comparisons, cumulative risk, 
and low exposure-dose-
response relationships. 
environmental exposure (benzene and ozone). Some molecular 
pathways are altered at all concentrations; other molecular and 
toxicological effects emerge with increasing dose. Molecular patterns 
that occur consistently across all concentrations appear preferable as 
biomarkers (EPA 2013a; Hatch et al. 2014; McCullough et al. 2014; 
Thomas R et al. 2014). 
 Pharmacological interventions have been shown to modify identified 
AOPs/AONs, and, concomitantly, the incidence or severity of the 
adverse outcomes (Cooper et al. 2013; Hatzimichael and Crook 2013; 
McCullough et al. 2014). 
 In comparison, the molecular data for PAH 
are considered suggestive of a causal 
association between PAH and lung cancer due 
to lack of an observed exposure-dose-
response relationship (likely due to 
uncertainties in exposure characterization), 
and data quality, analysis, and reporting 
limitations. Only about 8% of studies in Gene 
Expression Omnibus and ArrayExpress met 
study selection criteria. 
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  Additional evidence for the involvement of specific pathways in 
disease is provided by identification of naturally occurring human 
gene variants in the AONs that alter susceptibility and risks (Cooper 
et al. 2013; Hatzimichael and Crook 2013; Moreno-Macias et al. 
2013; Schlenk et al. 2008; Shen et al. 2011; Sillé et al. 2012; Smith et 
al. 2011; Vawda et al. 2014; Zhuo et al. 2012).  
 AONs are also disrupted by other chemical and nonchemical stressors 
known to alter the incidence of the specific disease/disorder under 
consideration; thus, AONs provide a tool for evaluating cumulative 
risks based on mechanistic commonalities (IARC 2012; Smith et al. 
2011; R Thomas et al. 2012). 
 Supporting data are provided by multiple molecular epidemiology and 
clinical studies and chronic animal bioassays and coherence with 
other systems biology data (e.g., NIH BioSystems: acute myeloid 
leukemia, lung cancer (small cell, non-small cell); BaP and cancer: 
(EPA 2013b, a). 
 Although species and in vitro differences exist, these examples 
provide consistent, coherent biologically plausible data linking 
specific omic alterations with specific diseases. 
Suggestive vs. likely: In general, molecular 
data alone associated with adverse outcomes 
are expected to be only suggestive or are 
inadequate for causal determination. To rise to 
likely, the following are generally necessary: 
 multiple, consistent, high-quality 
observational studies with similar results;  
 understanding of the cascade of events 
between molecular events to adverse 
outcomes, and experimental evidence 
showing that reversal of pathway alterations 
blocks or ameliorates adverse outcome; or 
 naturally occurring experiments where gene 
variants alter incidence or characteristic of 
disease.  
Important variables such as experimental 
paradigm (e.g., in vivo vs. in vitro), cell type, 
tissue type, and species also require 
consideration. Suggestive data are likely to be 
most useful for hypothesis generation, 
discovery, screening and prioritization, and 
potential augmentation of traditional data. 
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Knowledge mining and meta-
analysis prototype illustrated 
how large searchable databases 
can be used to identify, 
organize, integrate, and analyze 
existing data in an automated 
(computerized) fashion to 
 Knowledge mining and meta-analysis revealed associations 
between known exposures (biomonitoring) to several 
environmental agents and health effects (e.g., metals and persistent 
organic chemical) with prediabetes/diabetes using the Centers for 
Disease Control and Prevention’s National Health and Nutrition 
Assessment Examination Survey (NHANES). Human tissue 
biomarker and clinical outcome data are from the same individuals 
Suggestive to likely: Associative data 
presented here are suggestive and generally 
most useful for hypothesis generation. 
Categorization could rise to likely with the 
types of supporting data noted above under 
Tier 1 “Suggestive vs. likely” or integration of 
consistent, coherent, biologically plausible data 
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discover new insights into 
public health risks. 
(EPA 2015; Patel et al. 2012; Patel et al. 2013). 
 Supporting data are found in the literature (NIEHS 2015; Thayer et al. 
2012).  
 No systems biology context or Adverse Outcome Pathways (AOPs) or 
Adverse Outcome Networks (AONs) is available for data from 
NHANES. Information on biological context is available from the 
literature but currently not easily accessible in high- or medium-
throughput approaches (Audouze et al. 2013; Inadera 2013). 
 Also explored possible links among site-specific chemical exposures, 
ethnicity, genetic variants, and diabetes risks (Dimas et al. 2014; EPA 
2015; Patel and Cullen 2012). 
across data streams. 
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Short-duration in vivo 
exposure bioassays data use 
in either alternative or rodent 
species is illustrated in two 
prototypes. 
Short-duration, in vivo exposure bioassays—alternative 
(nonmammalian) species prototype e.g. zebrafish developmental 
assay results, characterization of thyroid-specific mechanisms, and 
predictive modeling of complex dose-response phenomena. Padilla 
et al. (2012) reported AC50s (concentration at 50% of maximum 
activity) in a zebrafish developmental assay for 305 chemicals. 
Potencies for individual chemicals and chemical classes were shown to 
range over several orders of magnitude (1 nM–80 µM). For certain 
classes of chemicals, 80–100% in the class tested positive (embryo 
death or structural defects). Perkins et al. (2013) illustrated the use of 
alternative species to help articulate mechanisms showing an AON for 
thyroid disruption with example toxicants and alternative models 
applicable to both human and ecological hazard assessment. Also 
discussed are how predictive models coupled to mechanistic 
understanding can be used to better characterize dose-response (Sipes 
et al. 2011), circadian variations (Eisenberg et al. 2008), and exposure 
window-response relationships (DeWoskin et al. 2014). For more 
details on alternative species bioassays see Ankley and Gray (2013), 
Perkins et al. (2013), and Villeneuve et al. (2014). 
Suggestive to likely within similar studies, 
coherent across different types of studies, and 
biologically plausible adverse phenotypic 
outcome data from nonmammalian, vertebrate 
species. Confidence is generally higher for 
evolutionarily conserved processes. 
 
Suggestive: 1) Transcriptomic changes 
correlated to adverse outcomes studies and 
coupled to AOPs/AONs or high-content assays 
with measurable adverse outcomes (e.g., 
zebrafish developmental assay) generally have 
greater evidentiary weight than initiating event 
assays (e.g., transcriptomic assays). Some 
systems biology context is needed for limited-
scope assessments for human risk (e.g., cross-
species conservation, AOPs/AONs). 
Alternative species outcome data alone are 
sufficient for ecological risk assessment. Cross-
species extrapolation and subchronic 
measurement of indicators introduces 
additional uncertainties as compared to human 
data discussed above. Reverse toxicokinetic 
models are needed to estimate equivalent 
human doses. 
Short-duration, in vivo exposure bioassays—rodent prototype 
correlated transcriptomic alterations with adverse outcomes, as 
determined in traditional bioassays for 10 chemicals (R Thomas et 
al. 2011; RS Thomas et al. 2012; RS Thomas et al. 2013). Consistency 
of the correlation between transcriptional changes and adverse effects 
across different exposure periods also was demonstrated (5 days to 13 
weeks) Transcriptional changes appeared at somewhat lower 
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concentrations than traditional effects. Transcriptomic studies alone 
cannot predict specific hazards but might be useful in relatively ranking 
chemical potencies to induce biologic alterations that might precede 
adverse outcomes. In general, transcriptomic data require some 
biologic context (e.g., AOPs/AONs) to increase confidence of biologic 
significance. 
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Quantitative structure 
activity relationship (QSAR) 
and molecular docking 
models are used to generate 
potency estimates and, with 
less confidence, hazards. Read-
across is also considered (i.e., 
filling data gaps for data-poor 
chemicals by analogy with 
structurally related, more data-
rich chemicals). 
QSAR models can predict chemical-specific toxicity values based 
on inherent chemical properties for some data-poor chemicals. 
 Models are developed based on chemical structures and known 
outcomes for data-rich chemicals (e.g., Goldsmith et al. 
2012;Venkatapathy and Wang 2013; Wang et al. 2011; Wang et al. 
2012a, 2012b). 
 Organisation for Economic Co-operation and Development (OECD) 
is harmonizing international use of QSAR hazard models and read-
across in the OECD QSAR toolbox (OECD 2014, 2015b, a). Also see 
EPA QSAR Guidance Document. (EPA 2012). 
 Often, the consensus of a suite of appropriate models is the preferred 
approach.  
 Often, models better predict potency than specific effects.  
 Issues exist around characterizing the uncertainty in QSAR and 
related read-across approaches and in the transparency of some 
models. Also see Ball et al. (2014)and Patlewicz et al. (2013) 
Suggestive to likely: TOPKAT Model 
predictions of potency when model is 
appropriate for chemicals evaluated; not 
generally predictive of dose-response for 
specific hazards; does generate a lowest-
observed-adverse-effect level for a subset of 
the data-poor chemicals that meet confidence 
criteria. Additional OECD models and read-
across can improve confidence in hazard 
characterization. 
High-throughput, in vitro 
bioassays and virtual tissue 
models are discussed.  
High-throughput in vitro assays based on biological process 
disruptions are interpreted in systems biology and AOP/AON contexts 
and in association with adverse outcomes (Attene-Ramos et al. 2013; 
EPA 2015; Judson et al. 2014; Tice et al. 2013). Also see Huang et al. 
2016. Virtual tissue modeling provides additional tools for evaluating 
data-limited chemicals (Knudsen et al. 2013).  
Suggestive: When coupled with understanding 
of the AOPs/AONs. Could rise to likely with 
the types of supporting data noted above under 
“Suggestive to likely.” 
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